We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Squamous cell carcinoma of the anal canal at The Queen Elizabeth Hospital: A local experience.
- Authors
Kichenadasse, Ganessan; Zakaria, Jasiah; Rodda, David J.; Hewett, Peter J.; Rieger, Nicholas A.; Stephens, Jacqueline H.; Pittman, Ken; Patterson, Kevin; Borg, Martin; Price, Timothy J.
- Abstract
Aim: Concurrent chemoradiotherapy is the standard treatment for squamous cell carcinoma of anal canal. We describe our experience of treating such patients at our center. Methods: Patients with anal squamous cell carcinoma were treated with a uniform sphincter preserving protocol at The Queen Elizabeth Hospital, South Australia. Standard radiotherapy along with 5-fluorouracil (750 mg/m2 on days 1–5 and days 29–32) and mitomycin C (12 mg/m2 on day 1 only) was given to eligible patients. Results: Of the 34 patients included in this study, nearly 60% were women. Most (89.3%) had T1-2 disease. One-third had nodal involvement. Twenty-seven had chemoradiotherapy, six had local excision alone and one had radiotherapy alone. Among those who had chemoradiation, 71.5% had a complete response and remained colostomy free until the last follow-up. Most completed the treatment without major side-effects. The 3 and 5-year disease free survival rate was 62% and 53%, respectively. All patients who failed chemoradiation underwent salvage surgery with a median survival time of 32.5 months. Conclusion: Sphincter preservation is the goal for anal cancers. Chemoradiotherapy is an important modality to achieve this goal.
- Subjects
RADIOTHERAPY; DRUG therapy; SQUAMOUS cell carcinoma; ANAL cancer; MITOMYCIN C
- Publication
Asia Pacific Journal of Clinical Oncology, 2007, Vol 3, Issue 4, p214
- ISSN
1743-7555
- Publication type
Article
- DOI
10.1111/j.1743-7563.2007.00115.x